In Situ Hybridization Market Players:
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott
- PerkinElmer, Inc.
- Leica Biosystems Nussloch GmbH
- F. Hoffman-La Roche Limited
- NeoGenomics Laboratories, Inc.
- Advanced Cell Diagnostics, Inc.
- BioView
- Agilent Technologies, Inc.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Oxford Gene Technology IP Limited
- Bio-Techne Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2026, the industry size of in situ hybridization is estimated at USD 1.84 Billion.
The global in situ hybridization market size was USD 1.84 Billion in 2026 and is expected to reach USD 3.83 Billion by the end of 2036, expanding at a CAGR of 7.6% during the forecast period, i.e., 2027-2036.
North America’s in situ hybridization market will dominate more than 45% share by 2036, fueled by rising healthcare spending and adoption of diagnostic technologies.
Key players in the market include Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited.
